GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Capex-to-Operating-Cash-Flow

Q32 Bio (Q32 Bio) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Q32 Bio's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $-14.55 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Q32 Bio Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Q32 Bio's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Capex-to-Operating-Cash-Flow Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
- - -

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of Q32 Bio's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Q32 Bio's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Capex-to-Operating-Cash-Flow falls into.



Q32 Bio Capex-to-Operating-Cash-Flow Calculation

Q32 Bio's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.005) / -18.677
=N/A

Q32 Bio's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -14.551
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Q32 Bio  (NAS:QTTB) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Q32 Bio Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Q32 Bio (Q32 Bio) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus